Drug Development for Cancer and Diabetes
  1. 362 pages
  2. English
  3. ePUB (mobile friendly)
  4. Available on iOS & Android
eBook - ePub

About this book

Key features include:



  • Details the role of plants for the treatment and management of cancer and diabetes




  • Discusses the role of phytocompounds as ligands for cancer and diabetic targets




  • Reviews plants and the potential of phytochemicals as antidiabetic and anticancer drugs




  • Explores the green biosynthesis of nanoparticles and their treatment efficiency

Trusted by 375,005 students

Access to over 1.5 million titles for a fair monthly price.

Study more efficiently using our study tools.

Information

Year
2020
eBook ISBN
9781000649949
Subtopic
Oncologia

PART I
Cancer and Leads for Cancer Treatment

CHAPTER 1

Biomarkers for Screening of Premalignant Lesions and Therapeutic Surveillance

CHUKWUEBUKA EGBUNA
Department of Biochemistry, Faculty of Natural Sciences, Chukwuemeka Odumegwu Ojukwu University, Anambra State – 431124, Nigeria, Tel.: +2347039618485, E-mails: [email protected], [email protected]

ABSTRACT

Biomarker, a portmanteau of “biological marker” is a naturally occurring molecule, gene, or characteristic capable of serving as a measurable indicator for some biological state or disease condition. Cancer biomarkers over time have gained lots of recognition for their usefulness in the early detection of cancer in symptomatic and asymptomatic patients, surveillance of patients with a high risk of cancer recurrence and as surrogate endpoint markers for primary prevention strategies. Biomarkers are also useful for the evaluation of potential drug therapies and drug developmental processes including drug developmental studies, safety measurements, proof of concept studies, and molecular profiling. This chapter provides an overview of the role of biomarkers in cancer research, screening, and drug development. It went further to detail the various cancer biomarkers utilized for screening, diagnosis, and prognosis.

1.1 INTRODUCTION

Cancer is a group of diseases that affects the human body. It manifests through the proliferation of previously healthy cells into tumor cells by some causative factors. Different types of cancers numbering over 200 are now known and classified based on the type of cell that is initially affected. For instance, cancers arising from epithelial cells are called carcinoma, those from connective tissue are called sarcoma, and those from hematopoietic (blood-forming) are called lymphoma and leukemia while those from pluripotent cells and immature “precursor” cells/embryonic tissue are respectively known as germ cell tumor and blastoma. The transformation of healthy cells can give rise to tumor cells which eventually becomes cancer through a multistage process usually from a pre-cancerous lesion to a malignant tumor (WHO, 2018a). In the disease condition, old cells do not die, instead grows out of control, forming new abnormal cells. These abnormal cells often result in a tumor although some kinds of cancers do not form tumors, e.g., leukemia. The tumor can grow and obstruct the function of the nervous, digestive, and circulatory systems, with the possibility of releasing hormones that can alter the body functions. Tumors that do not spread and with limited growth are called benign tumors while those capable of spreading are called a malignant tumor. There are six hallmarks criterion for malignant tumor formation. They include cell growth and division, continuous growth and division even when given contrary signals, circumventing programmed cell death, uncontrolled number of cell divisions, promoting blood vessel construction, metastases formation and invasion of tissue (Hanahan and Weinberg, 2000). The potential signs and symptoms of cancer include unusual bleeding or discharge (blood in the urine, bleeding between periods, blood during cough and vomit), lump in the breast, coughing, chest pain and breathlessness, changes in bowel or bladder habits, indigestion or difficulty in swallowing, a sore that does not heal, obvious changes is warts or moles, and unexplained weight loss.
In the United States alone, cancer is notoriously the second leading cause of death after heart disease which has retained the number one spot for the past 15 years (CDC, 2017). One-half of men and one-third of women have a lifetime cancer risk. In 2015, about 90.5 million people worldwide had cancer which resulted in 8.8 million deaths (15.7% of deaths) (GBD, 2016). Yearly, about 14.1 million new cases occur excluding skin cancer. According to WHO (2018a), the most prevalent type of cancers is lung cancer which caused 1.69 million deaths, liver cancer which caused 788,000 deaths, the colorectal cancer which led to 774,000 deaths, stomach cancer which caused 754,000 deaths and the breast cancer which caused 571,000 deaths. Approximately, 70% of these deaths occur in the low- and middle-income countries. This may partly be because of the lack of early-stage screening facilities or poor diagnostic conditions. In 2017, it was found that only 26% of low-income countries have pathology services available in the public sector compared to more than 90% for high-income countries (WHO, 2018a). Globally, about one in six deaths are caused by cancer. A major fraction, 90–95% of cases of cancer, are as a result of genetic mutations which is influenced by environmental factors (not genetically inherited, e.g., lifestyle, behavioral, and economic factors), while the remaining 5–10% cases of cancer are due to inherited genetics (Anand et al., 2008). From records, it was found that one-third of deaths from cancer are linked to five leading behavioral and dietary risks. These are high body mass index, lack of physical activity or exercise, low consumption of fruits and vegetables, tobacco, and alcohol use. These factors culminate between a person’s genetic factors and three categories of external agents, including: physical carcinogens, such as radiations (ultraviolet, ionizing radiation, etc.); chemical carcinogens, e.g., asbestos, benzidine, aristolochic acids, mists from strong inorganic acids, e.g., sulfuric acid, formaldehyde, aflatoxin (a food contaminant), tobacco smoke components, arsenic; biological carcinogens, e.g., infections of certain viruses (e.g., human papillomavirus (HPV), Hepatitis B and C viruses, Kaposi sarcoma-associated herpesvirus (KSHV) and human T-cell leukemia/lymphoma virus type-1 (HTLV-1), bacteria (e.g., Helicobacter pylori), or parasites (e.g., Opisthorchis viverrini, Schistosoma haematobium). Up to 25% of cancer cases result from hepatitis and HPV infections in low- and middle-income countries (Plummer et al., 2016).
According to the American Cancer Society (2018), the increasing cases of deaths from cancer can be prevented by systematic approach by improved lifestyle through proper dieting and physical activity, reduction of tobacco use, good dieting, physical activities, and the use of tobacco and application of established screening tests. It can reduce death from cancer. In 2010, the total annual economic cost of cancer was estimated to be US$ 1.16 trillion (Stewart et al., 2014). However, there appear some prospects from the advent of new techniques for cancer research in molecular biology and biochemistry together with the declaration of “War on Cancer.”

1.1.1 EARLY DETECTION OF CANCER

The destructive effects of cancer can be reduced if cases are detected and treated early. The early detection of cancer may lead to decreased morbidity with improved survival, and in some situations treatment may require only surgery if identified early enough (Schiffman et al., 2015). The two basic components of early detection are early diagnosis and screening. In early detection, education plays a vital role in creating awareness for possible warning signs of cancer, among physicians, nurse...

Table of contents

  1. Cover
  2. Half Title
  3. Title Page
  4. Copyright Page
  5. About the Editors
  6. Contents
  7. Contributors
  8. Abbreviations
  9. Foreword
  10. Preface
  11. PART I: CANCER AND LEADS FOR CANCER TREATMENT
  12. PART II: ANTIDIABETIC DRUG DISCOVERY
  13. Index

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn how to download books offline
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.5M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1.5 million books across 990+ topics, we’ve got you covered! Learn about our mission
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more about Read Aloud
Yes! You can use the Perlego app on both iOS and Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app
Yes, you can access Drug Development for Cancer and Diabetes by K. Saravanan, Chukwuebuka Egbuna, Horne Iona Averal, S. Kannan, S. Elavarasi, Bir Bahadur, K. Saravanan,Chukwuebuka Egbuna,Horne Iona Averal,S. Kannan,S. Elavarasi,Bir Bahadur in PDF and/or ePUB format, as well as other popular books in Medicina & Oncologia. We have over 1.5 million books available in our catalogue for you to explore.